CBD Gummies and Mycotoxins: What Buyers Should Know

CBD Gummies and Mycotoxins: What Buyers Should Know

Mycotoxins are toxic secondary metabolites produced by certain mold species that colonize agricultural crops, including hemp. They are chemically stable, heat-resistant compounds that persist through processing — meaning that if mycotoxin-contaminated hemp enters a supply chain, those toxins can survive extraction, decarboxylation, and gummy manufacturing and appear in the finished product a consumer ingests. For buyers of CBD gummies, mycotoxin testing is a distinct safety panel from microbial testing — it measures the chemical byproducts of fungal contamination, not the living organisms themselves. A product can pass yeast and mold counts while still carrying mycotoxins from earlier-stage contamination that has since been controlled. This article covers the mycotoxins most relevant to hemp products, where they come from, how testing works, and what to look for on a COA.

Why Hemp Is a Mycotoxin Risk Crop

Hemp used in CBD gummies cultivation creates conditions favorable to mycotoxin-producing molds. Dense flowering canopies trap moisture and create humid microenvironments where Aspergillus, Fusarium, and Penicillium species thrive. Outdoor hemp grown in humid climates — significant portions of U.S. hemp production occur in states with high summer humidity — is particularly susceptible. Post-harvest handling and storage are additional risk points: improperly dried hemp (above 12–15% moisture content) can develop mold colonies rapidly, producing mycotoxins before the crop reaches the extraction facility. [PMID 32658857]

The extraction step concentrates plant compounds — and that concentration process applies to mycotoxins as well as cannabinoids. If raw hemp with low but detectable mycotoxin levels is used for extraction, the resulting oil may carry elevated mycotoxin concentrations relative to the starting biomass. This makes finished-product testing especially important for mycotoxins, as the concentration factor in extraction can move borderline raw material results into concerning ranges in the extract or finished edible. [PMID 30624194]

The Four Aflatoxins and Total Aflatoxin Limits

Aflatoxins are produced primarily by Aspergillus flavus and Aspergillus parasiticus — mold species commonly found on agricultural crops including corn, peanuts, tree nuts, and hemp. There are four main aflatoxins of regulatory concern: B1, B2, G1, and G2, designated by their fluorescence characteristics under UV light (blue and green). Aflatoxin B1 is the most potent naturally occurring carcinogen known — the International Agency for Research on Cancer (IARC) classifies it as a Group 1 human carcinogen, meaning there is sufficient evidence of carcinogenicity in humans. [PMID 28885619]

Regulatory limits for aflatoxins in dietary supplements and food products vary by jurisdiction:

• FDA action levels for food: Total aflatoxins ≤20 ppb (μg/kg); aflatoxin M1 in milk ≤0.5 ppb. These are action levels for enforcement, not formal limits, and reflect practical achievability in the food supply rather than toxicological ideals.
• USP dietary supplement limits: Total aflatoxins (B1+B2+G1+G2) ≤20 ppb; aflatoxin B1 alone ≤5 ppb
• European Union: Total aflatoxins ≤10 ppb in food, B1 ≤5 ppb — stricter than U.S. standards
• California Prop 65: Aflatoxin B1 has a no-significant-risk level (NSRL) of 0.02 μg/day — applying the most stringent Prop 65 limits to high-dose supplement use can require very low product concentrations

On a COA for CBD gummies, aflatoxin results are typically reported as individual compound concentrations in ppb, with a summed total. All results should fall well below 20 ppb total, with B1 preferably non-detect given its potency as a carcinogen. Non-detect results across all four aflatoxins is the expected outcome for responsibly sourced hemp products.

Ochratoxin A

Ochratoxin A (OTA) is produced by Aspergillus ochraceus, A. carbonarius, and various Penicillium species. It is a nephrotoxin — primarily targeting the kidneys — with potential immunosuppressive and carcinogenic properties. IARC classifies OTA as Group 2B (possibly carcinogenic to humans). OTA is particularly problematic for individuals with pre-existing kidney disease or impaired renal function, and has been detected in a wide range of agricultural commodities including grains, wine, coffee, dried fruits, and hemp. [PMID 26931579]

Regulatory limits for OTA in dietary supplements vary. The European Food Safety Authority (EFSA) has established a tolerable weekly intake (TWI) of 120 ng/kg body weight per week. USP dietary supplement limits set OTA at ≤20 ppb in botanical supplements, though some state-regulated cannabis markets apply stricter limits (California cannabis edibles: OTA ≤20 ppb). A COA showing OTA at non-detect or well below 20 ppb indicates adequate raw material quality and supplier controls.

Fumonisins and Other Fusarium Mycotoxins

Fusarium species produce a range of mycotoxins including fumonisins (B1, B2), deoxynivalenol (DON, also called vomitoxin), zearalenone (ZEA), and trichothecenes. These are primarily grain crop concerns — corn, wheat, barley — but hemp grown in proximity to grain fields or in humid environments can also carry Fusarium contamination.

Fumonisins are classified as Group 2B possible carcinogens, with effects including esophageal cancer risk at high chronic exposures in populations with corn-heavy diets. They are less commonly detected at concerning levels in hemp than aflatoxins or OTA, but comprehensive mycotoxin panels include them. Zearalenone is an estrogenic compound that can disrupt hormonal signaling at chronic exposures. DON is primarily a gastrointestinal irritant with vomiting and nausea as the primary acute effects.

Not all COAs for CBD gummies test for the full Fusarium mycotoxin panel. A COA that tests only for aflatoxins and OTA covers the most common and potent mycotoxins in hemp, but may miss Fusarium-derived contaminants. Panels that include fumonisin B1/B2, ZEA, and DON offer more comprehensive mycotoxin coverage, particularly for hemp grown in the Midwest or Southeast where Fusarium pressure is higher. [PMID 29562591]

How Mycotoxin Testing Is Performed

Mycotoxin testing for CBD gummies typically uses liquid chromatography-tandem mass spectrometry (LC-MS/MS), which provides both compound identification and quantification at the ppb and sub-ppb levels required for regulatory compliance. Immunoassay-based lateral flow tests (similar to home test strips) can be used for rapid screening but are less sensitive and specific than LC-MS/MS and are generally not considered sufficient for a COA intended as a quality verification document.

For finished gummy products, sample preparation involves extraction of mycotoxins from the gummy matrix using organic solvents, followed by cleanup (often with immunoaffinity columns to remove matrix interferences), then LC-MS/MS analysis. The gummy matrix — high sugar content, gelatin or pectin, oil-soluble cannabinoids — requires validated sample preparation to ensure mycotoxins partition correctly from the matrix into the analytical extract. Method validation for the specific gummy matrix is important; a method validated only for hemp flower or oil extract may have poor recovery in a gummy matrix. [PMID 31072133]

Mycotoxins vs. Microbial Counts: Why Both Panels Are Needed

A common misconception is that passing microbial counts (total yeast and mold) means mycotoxins are also absent. These are separate and distinct measurements that do not substitute for each other. A product's current mold count reflects the living fungal organisms present at the time of testing. Mycotoxins, by contrast, are stable chemical compounds produced before, during, or after mold growth that persist regardless of whether the producing mold is still viable.

Hemp biomass that experienced mold contamination during drying or storage, then was processed in a way that killed the mold organisms (solvent extraction, CO2 extraction, heat treatment), can yield an extract with a very low yeast and mold count — potentially passing the TYMC test — while still carrying the mycotoxins produced by the mold before it was killed. This means a CBD gummy COA with clean microbial results is not evidence of mycotoxin safety unless a separate mycotoxin panel is also present and passing.

Reading Mycotoxin Results on a COA

A mycotoxin panel on a COA for CBD gummies should include at minimum:

• Aflatoxin B1, B2, G1, G2 (individual and total)
• Ochratoxin A

A more comprehensive panel adds fumonisin B1 and B2, zearalenone, and deoxynivalenol. Each compound result should be reported in ppb (μg/kg) with the action limit and a pass/fail determination. Results reported as "ND" (non-detect) or "

The action limits stated on the COA should be consistent with recognized standards. If a COA shows an action limit of 100 ppb for total aflatoxins — far above the 20 ppb standard — that either reflects a typographical error or the use of a non-standard limit. Either possibility warrants follow-up with the manufacturer.

Supply Chain Controls and Mycotoxin Prevention

Mycotoxin prevention in hemp products destined for CBD gummies begins before extraction. Responsible suppliers test incoming hemp biomass for mycotoxins before it enters production. Moisture monitoring during harvest and storage is critical — hemp dried to below 12% moisture within 24–48 hours of harvest has dramatically lower mold risk than hemp that is slow-dried or improperly stored. Climate-controlled storage facilities further reduce post-harvest mycotoxin development.

Some manufacturers source hemp exclusively from regions with lower mycotoxin risk profiles — the Pacific Northwest and high-altitude growing regions tend to have lower humidity and fewer Aspergillus-favorable conditions than the Southeast or Midwest. Certified organic hemp does not inherently have lower mycotoxin risk — organically approved fungicides do not include the most effective mold preventatives — but organic certification does provide documentation of agricultural practices that can be evaluated for mycotoxin risk factors. [PMID 29482741]

For consumers evaluating CBD gummies, the most actionable signal is whether the COA includes a mycotoxin panel with numeric results, not merely a summary pass. A manufacturer willing to show the actual numbers — particularly aflatoxin B1 and OTA — demonstrates transparency that a summary pass statement alone does not.

Mycotoxin COA Checklist

☐ A separate mycotoxin panel exists. Confirm the COA includes mycotoxin testing distinct from the microbial (yeast and mold) panel. The two measure fundamentally different things.

☐ Aflatoxins B1, B2, G1, G2 are all tested. Individual results for each of the four aflatoxins should be present, not only a total.

☐ Total aflatoxins are ≤20 ppb. The combined B1+B2+G1+G2 result should fall well below this limit; non-detect is the preferred outcome.

☐ Aflatoxin B1 is at or near non-detect. Given its potency as a carcinogen, B1 should be as close to zero as the method's detection limit allows.

☐ Ochratoxin A is tested and ≤20 ppb. OTA is the second most important mycotoxin parameter for hemp products; its absence should be confirmed.

☐ Numeric results are reported. A "pass" summary without numeric concentrations is insufficient — the actual values allow evaluation of margin to the action limit.

☐ Action limits are consistent with recognized standards. Limits should be at or below 20 ppb for total aflatoxins and 20 ppb for OTA. Significantly higher limits may indicate use of a non-standard reference.

☐ The sample is the finished gummy. Extract-level mycotoxin results may understate finished-product levels if dilution factors between extract and gummy differ from assumptions; finished-product testing is the definitive standard.

☐ Lot number matches your product. Mycotoxin contamination is batch-specific and depends on the specific hemp crop and storage conditions for that harvest lot.

Disclaimer: This article is for informational and educational purposes only. Mycotoxin standards referenced reflect U.S. dietary supplement and food regulatory contexts as of publication. Standards may evolve and vary by jurisdiction. This article does not constitute medical advice.